Email:
Media
News Center
Nov. 15
2022
A Subsidiary of CSPC Passes EcoVadis Social Responsibility Certification
Recently, EcoVadis, a global corporate social responsibility (CSR) evaluation authority, completed the social responsibility audit and certification of Hebei Huarong Pharmaceutical Co., Ltd. (Huarong Pharmaceutical), a subsidiary of CSPC.
Oct. 28
ANTIBODY-DRUG CONJUGATE “SYS6002” OBTAINS CLINICAL TRIAL APPROVAL
The antibody-drug conjugate “SYS6002" developed by the Group has obtained clinical trial approval granted by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China.
Oct. 25
“TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS” OBTAINS DRUG REGISTRATION APPROVAL
“Tofacitinib Citrate Extended-Release Tablets (11mg)” developed by CSPC has obtained drug registration approval granted by the National Medical Products Administration of the People’s Republic of China.
Latest Results of Duomeisu in the Treatment of Sarcoma Released
A study about Duomeisu was successfully published in the journal of Clinical Cancer Research (IF: 13.801, JCR Division: Medical Division 1).
Oct. 12
EXCLUSIVE LICENSE AGREEMENT FOR BATOCLIMAB (HBM9161)
CSPC entered into an exclusive license agreement with “Shanghai HBM”,pursuant to which CSPC obtained an exclusive license from Shanghai HBM to develop, manufacture and commercialize batoclimab (HBM9161) in Greater China.
Sep. 23
“LENALIDOMIDE CAPSULES” OBTAINS DRUG REGISTRATION APPROVAL
“Lenalidomide Capsules (25mg)"developed by CSPC has obtained drug registration approval granted by the National Medical Products Administration of the People’s Republic of China, and is deemed to have passed the consistency of quality and efficacy evaluation of generic drugs.
Contact Us
Phone:
+86 311 8703 7015
Products
Science
About Us
